LTA/TNF-β Cancer Research Results

LTA/TNF-β, LTA / TNF-β / lymphotoxin-α: Click to Expand ⟱
Source:
Type:
Tumor Necrosis Factor-beta (TNF-β), also known as Lymphotoxin-alpha (LT-α), is a cytokine involved in systemic inflammation and one of the cytokines that make up the tumor necrosis factor family.
TNF-β is typically high expression in cancers with poor prognosis.
Field Suggested Entry
Target LTA / lymphotoxin-α / TNF-β
Full Name Lymphotoxin alpha
Target Class TNF-superfamily cytokine
Main Receptors TNFR1/TNFRSF1A, TNFR2/TNFRSF1B, HVEM/TNFRSF14; LTBR/TNFRSF3 when complexed with LTB
Primary Biology Lymphocyte-derived inflammatory signaling, immune activation, antiviral response, apoptosis signaling, lymphoid tissue organization, secondary lymphoid organ development
Cancer Relevance Medium and context-dependent: may contribute to tumor-cell cytotoxicity, cancer immunity, lymphoid-structure formation, chronic inflammation, and tumor microenvironment remodeling depending on context
AD Relevance Low-medium: indirect relevance through TNF-family neuroinflammation; less established than TNF-α, TNFR1, or TNFR2
Therapeutic Direction Context-dependent. Suppress excessive/pathological inflammatory signaling where appropriate, but avoid assuming that LTA inhibition is always beneficial because lymphotoxin signaling can also support immune defense and tumor surveillance.


Scientific Papers found: Click to Expand⟱
6594- Anamu,    Dibenzyl trisulfide induces caspase-independent death and lysosomal membrane permeabilization of triple-negative breast cancer cells
- in-vitro, BC, HCC1806/CRL-2335 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
TumCP↓, TumCMig↓, Bak↑, GADD45A↑, LTA/TNF-β↑, lysoMP↑, P450↓, cl‑PARP↑, Dose↝,
1304- ASA,    Aspirin Inhibits Colorectal Cancer via the TIGIT-BCL2-BAX pathway in T Cells
- in-vitro, CRC, NA - in-vivo, NA, NA
TumCP↓, Apoptosis↑, Bcl-2↓, BAX↑, IL10↓, LTA/TNF-β↓,
5742- Buty,    Butyrate: A Double-Edged Sword for Health?
- Review, Var, NA
HCAR2↑, Inflam↓, HDAC↓, *IFN-γ↓, *TNF-α↓, *IL1β↓, *IL6↓, *IL8↓, *IL10↑, *LTA/TNF-β↑, *NF-kB↓, *ROS↓, PPARγ↓, Weight↓,
3320- SIL,    Neuroprotective Potential of Silymarin against CNS Disorders: Insight into the Pathways and Molecular Mechanisms of Action
- Review, AD, NA
*hepatoP↑, *neuroP↑, *ROS↓, *β-Amyloid↓, *Inflam↓, *Aβ↓, *NF-kB↓, *TNF-α↓, *LTA/TNF-β↓, *iNOS↓, *NO↓, *COX2↓,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

PPARγ↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   Bak↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   lysoMP↑, 1,  

Kinase & Signal Transduction ⓘ

HCAR2↑, 1,  

DNA Damage & Repair ⓘ

GADD45A↑, 1,   cl‑PARP↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

HDAC↓, 1,  

Migration ⓘ

TumCMig↓, 1,   TumCP↓, 2,  

Immune & Inflammatory Signaling ⓘ

HCAR2↑, 1,   IL10↓, 1,   Inflam↓, 1,   LTA/TNF-β↓, 1,   LTA/TNF-β↑, 1,  

Drug Metabolism & Resistance ⓘ

Dose↝, 1,   P450↓, 1,  

Functional Outcomes ⓘ

Weight↓, 1,  
Total Targets: 20

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

ROS↓, 2,  

Cell Death ⓘ

iNOS↓, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IFN-γ↓, 1,   IL10↑, 1,   IL1β↓, 1,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 1,   LTA/TNF-β↓, 1,   LTA/TNF-β↑, 1,   NF-kB↓, 2,   TNF-α↓, 2,  

Protein Aggregation ⓘ

Aβ↓, 1,   β-Amyloid↓, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,  

Functional Outcomes ⓘ

hepatoP↑, 1,   neuroP↑, 1,  
Total Targets: 19

Scientific Paper Hit Count for: LTA/TNF-β, LTA / TNF-β / lymphotoxin-α
1 DTS(dibenzyl trisulphide) from Anamu
1 Aspirin
1 Butyrate
1 Silymarin (Milk Thistle) silibinin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:914  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page